ArticleMeta gene2016
Genetic polymorphisms of interleukin genes and the risk of Alzheimer's disease: An update meta-analysis.
Article in Meta gene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Association of Interleukin-1 gene clusters polymorphisms with primary open-angle glaucoma: a meta-analysis.BMC ophthalmology · 2017Pooled it
- Development of Plasma Protein Classification Models for Alzheimer's Disease Using Multiple Machine Learning Approaches.International journal of molecular sciences · 2025Article
- Peripheral Inflammation and Insulin Resistance: Their Impact on Blood-Brain Barrier Integrity and Glia Activation in Alzheimer's Disease.International journal of molecular sciences · 2025Review
- Dysregulated interleukin networks drive immune heterogeneity in Alzheimer's disease: an immunogenomic approach to subgroup classification and predictive modeling.BMC neurology · 2025Article
- Brain interleukins and Alzheimer's disease.Metabolic brain disease · 2025Review
- Associations between IL-1β, IL-6, and TNFα polymorphisms and longitudinal trajectories of cognitive function in non-demented older adults.Brain, behavior, & immunity - health · 2024Article
- DNA hypomethylation promotes the expression of CASPASE-4 which exacerbates inflammation and amyloid-β deposition in Alzheimer's disease.Alzheimer's research & therapy · 2024Article
- The Link Between COVID-19 and Alzheimer Disease Through Neuroinflammation.Clinical medicine & research · 2023Article
- Genetic Polymorphisms in Oxidative Stress and Inflammatory Pathways as Potential Biomarkers in Alzheimer's Disease and Dementia.Antioxidants (Basel, Switzerland) · 2023Article
- Anti-Inflammatory Gene Therapy Improves Spatial Memory Performance in a Mouse Model of Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2022Article
- PLCγ2 impacts microglia-related effectors revealing variants and pathways important in Alzheimer's disease.Frontiers in cell and developmental biology · 2022Review
- COVID-19 and Alzheimer's Disease.Brain sciences · 2021Review
- Immune System and Neuroinflammation in Idiopathic Parkinson's Disease: Association Analysis of Genetic Variants and miRNAs Interactions.Frontiers in genetics · 2021Article
- Inflammation and Insulin Resistance as Risk Factors and Potential Therapeutic Targets for Alzheimer's Disease.Frontiers in neuroscience · 2021Review
- Associations ofFrontiers in aging neuroscience · 2021Article
- Investigation of Genetic Variations ofLife (Basel, Switzerland) · 2020Article
- The Regulatory Role of IL-10 in Neurodegenerative Diseases.Biomolecules · 2020Review
- Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI.Experimental and therapeutic medicine · 2020Article
- Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine.Pharmacology & therapeutics · 2019Review
- Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer's disease.Journal of neuroinflammation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRecently, several meta-analyses have reported an association between interleukin (IL) gene polymorphisms and the risk of Alzheimer's disease (AD). Several further papers discussing the relationship with the risk of AD have recently been published. The aim of this meta-analysis was to re-evaluate and update the associations between IL gene polymorphisms and the risk of AD.
methodsThe search sources were PubMed, Science Direct, Scopus, and Google Scholar up to July 2015, and the following search terms were used: "interleukin 1 or interleukin 6 or interleukin 10" and "variant or polymorphism or SNP" in combination with "Alzheimer's disease". A meta-analysis using the pooled odds ratios and 95% confidence intervals was carried out to assess the associations between four polymorphisms of IL genes (- 889C > T in IL-1α, - 511C > T in IL-1β, - 174G > C in IL-6 and - 1082G > A in IL-10) and the risk of AD under the heterozygous, homozygous, dominant, and recessive models with fixed- or random-effects models.
resultsA total of 21,864 cases and 40,321 controls from 93 individual studies were included in this meta-analysis. Our results indicated that the - 889C > T polymorphism was strongly associated with the increased risk of AD. However, three polymorphisms were not associated with the risk of AD.
conclusionsSimilar to previous meta-analyses, our updated meta-analysis suggested that the - 889C > T polymorphism may be a factor in AD. However, the results of our meta-analysis of the - 174G > C polymorphism differed from those of previous meta-analyses. Consequently, we suggest that the - 174G > C polymorphism may not be a risk factor for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.